CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Clinical Trial Description

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors Main Study - Group 1 and Group 2 all HER2 overexpressing solid tumors Intraperitoneal Substudy - HER2 overexpressing peritoneal disease 89[Zr] radiolabeled CT-0508 Substudy - All HER2 overexpressing solid tumors (Univ of Penn, Abramson Cancer Center only) CT-0508 Combination with Pembrolizumab Substudy - All HER2 overexpressing solid tumors ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Bile Duct Cancer
Bile Duct Neoplasms
Biliary Tract Cancer
Biliary Tract Neoplasms
Bladder Cancer
Breast Cancer
Breast Neoplasm
Breast Neoplasms
Cancer
Carcinoma
Carcinoma, Ductal
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Carcinoma, Ovarian Epithelial
Carcinoma, Small Cell
Carcinoma, Squamous
Carcinoma, Squamous Cell
Carcinoma, Transitional Cell
Colorectal Cancer
Endometrial Cancer
Endometrial Neoplasms
Esophagogastric Junction Neoplasms
Head and Neck Cancer
Head and Neck Neoplasms
HER-2 Gene Amplification
HER-2 Protein Overexpression
HER2-positive
HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Solid Tumors
Inflammatory Breast Cancer
Lung Cancer, Small Cell
Lung Neoplasms
Malignant Neoplasms
Neoplasms
Ovarian Neoplasms
Pancreatic Cancer
Prostate Cancer
Prostatic Neoplasms
Small Cell Lung Carcinoma
Stomach Neoplasms

Clinical Trial Details

NCT number	NCT04660929
Study type	Interventional
Source	Carisma Therapeutics Inc
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	February 2, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04681911` - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer	Phase 2
Terminated	`NCT04066790` - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer	Phase 2
Completed	`NCT04890327` - Web-based Family History Tool	N/A
Completed	`NCT03591848` - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility	N/A
Recruiting	`NCT03954197` - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients	N/A
Terminated	`NCT02202746` - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Phase 2
Active, not recruiting	`NCT01472094` - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed	`NCT06049446` - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn	`NCT06057636` - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study	N/A
Recruiting	`NCT05560334` - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations	Phase 2
Active, not recruiting	`NCT05501769` - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer	Phase 1
Recruiting	`NCT04631835` - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer	Phase 1
Completed	`NCT04307407` - Exercise in Breast Cancer Survivors	N/A
Recruiting	`NCT03544762` - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation	Phase 3
Terminated	`NCT02482389` - Study of Preoperative Boost Radiotherapy	N/A
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Completed	`NCT00226967` - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting	`NCT06019325` - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy	N/A
Recruiting	`NCT06006390` - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06037954` - A Study of Mental Health Care in People With Cancer	N/A